| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.57 | 12.18 | 54.41 | 5.97 |
Op profit growth | 19.2 | 3.1 | 93.35 | -15.35 |
EBIT growth | 14.8 | -1.65 | 80.53 | -21.86 |
Net profit growth | -12.43 | -1.02 | 100.91 | -39.16 |
Profitability ratios (%) | ||||
OPM | 24.07 | 23.13 | 25.17 | 20.1 |
EBIT margin | 16.72 | 16.69 | 19.03 | 16.28 |
Net profit margin | 7.92 | 10.36 | 11.75 | 9.03 |
RoCE | 9.58 | 10.3 | 13.36 | 8.59 |
RoNW | 2.01 | 2.58 | 3.14 | 1.85 |
RoA | 1.13 | 1.59 | 2.06 | 1.19 |
Per share ratios (₹) | ||||
EPS | 6.43 | 7.05 | 7.26 | 7.55 |
Dividend per share | 0.5 | 0 | 0 | 1 |
Cash EPS | -1.38 | 0.21 | 1.63 | -0.21 |
Book value per share | 70.23 | 63.55 | 55.88 | 86.34 |
Valuation ratios | ||||
P/E | 52.02 | 57.98 | 37.27 | 39.35 |
P/CEPS | -242.25 | 1,931.33 | 165.67 | -1,403.62 |
P/B | 4.76 | 6.43 | 4.84 | 3.44 |
EV/EBIDTA | 19.95 | 27.01 | 19.37 | 34.63 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 16.11 |
Tax payout | -16.25 | -19.52 | -27.46 | -25.72 |
Liquidity ratios | ||||
Debtor days | 79.42 | 69.67 | 65.56 | 86.17 |
Inventory days | 92.87 | 84.37 | 61.86 | 60.09 |
Creditor days | -112.21 | -121.03 | -113.98 | -119.99 |
Leverage ratios | ||||
Interest coverage | -20.24 | -20.66 | -18.67 | -10.91 |
Net debt / equity | 0.4 | 0.32 | 0.25 | 0.18 |
Net debt / op. profit | 1.72 | 1.49 | 1.07 | 1.13 |
Cost breakup (₹) | ||||
Material costs | -33.21 | -31.41 | -32.23 | -39.67 |
Employee costs | -22.97 | -24.37 | -22.91 | -22.58 |
Other costs | -19.73 | -21.07 | -19.68 | -17.63 |
Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.
The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.
Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza.
As per the company, YESINTEK shall be available in all the same formulations currently provided by Stelara.
Here are some of the stocks that may see significant price movement today: Biocon, NTPC Green Energy, LIC, etc.
Biocon's EBITDA increased by 16% YoY to ₹787 crore, which shows improved operational performance.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Just Dial, PCBL, etc.
The approval further adds to Biocon's portfolio of complex drug products and will be commercialised in the region expeditiously
Here are some of the stocks that may see significant price movement today: Varun Beverages, NHPC, Hindustan Zinc, etc.
The USFDA released an Establishment Inspection Report with a "Voluntary Action Indicated" status for Biocon's Active Pharmaceutical Ingredients facility in Bengaluru.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
